bioAffinity Technologies (BIAF) Return on Sales (2022 - 2026)

bioAffinity Technologies (BIAF) has reported Return on Sales for 5 consecutive years, with 0.03% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Sales fell 1.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (down 2.0% YoY), while the FY2025 annual figure was 0.02%, down 1.0% from the prior year.
• Return on Sales eased to 0.03% in Q1 2026 per BIAF's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2024 and bottomed at 42.78% in Q3 2022.
• Historically, Return on Sales has averaged 4.27% across 5 years, with a median of 0.03% in 2025.
• On a YoY basis, Return on Sales climbed as much as 4270 bps in 2023 and fell as far as 21 bps in 2023.
• bioAffinity Technologies' Return on Sales stood at 7.14% in 2022, then soared by 100 bps to 0.01% in 2023, then declined by 25 bps to 0.01% in 2024, then plunged by 47 bps to 0.02% in 2025, then plunged by 36 bps to 0.03% in 2026.
• Business Quant data shows BIAF's Return on Sales at 0.03% in Q1 2026, 0.02% in Q4 2025, and 0.03% in Q3 2025.